Arun Wiita, MD, PhD

Director, UCSF Stephen and Nancy Grand Multiple Myeloma Translational Initiative Laboratory
Assistant Director, UCSF Clinical Cytogenetics Laboratory
Associate Professor
Department of Laboratory Medicine
+1 415 514-6238
Research Overview: 

Our laboratory is focused on using mass spectrometry-based proteomics to discover new biology and therapeutic targets in hematologic malignancies (blood cancers) and genetic disease. Our major hypothesis is that “biology happens at the protein level” – i.e. RNA-level analysis is not enough. This is particularly true when investigating biological signatures driven by protein post-translational modifications, protein-protein interactions, and altered sub-cellular localization.

To achieve these goals, our inter-disciplinary group aims to integrate proteomics-based screening with “multi-omics” bioinformatics, clinical data, epigenetic methods, genome engineering, antibody engineering, cellular engineering, chemical biology, and mechanistic biology. In particular, significant efforts in the lab are focused on developing new proteomics methods to discover cell surface targets, and then utilize emerging protein and cellular engineering approaches to develop novel cancer immunotherapies to eliminate disease.

Primary Thematic Area: 
Cancer Biology & Cell Signaling
Secondary Thematic Area: 
Research Summary: 
We are interested in utilizing proteomic methodologies to uncover new therapeutic targets in blood cancers, and then developing new cellular therapies to treat disease based on these discoveries.



Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.

bioRxiv : the preprint server for biology

Glasgow A, Glasgow J, Limonta D, Solomon P, Lui I, Zhang Y, Nix MA, Rettko NJ, Lim SA, Zha S, Yamin R, Kao K, Rosenberg OS, Ravetch JV, Wiita AP, Leung KK, Zhou XX, Hobman TC, Kortemme T, Wells JA

Variants of uncertain significance in prenatal microarrays: a retrospective cohort study.

BJOG : an international journal of obstetrics and gynaecology

Mardy AH, Wiita AP, Wayman BV, Drexler K, Sparks TN, Norton ME

Signalling input from divergent pathways subverts B cell transformation.


Chan LN, Murakami MA, Robinson ME, Caeser R, Sadras T, Lee J, Cosgun KN, Kume K, Khairnar V, Xiao G, Ahmed MA, Aghania E, Deb G, Hurtz C, Shojaee S, Hong C, Pölönen P, Nix MA, Chen Z, Chen CW, Chen J, Vogt A, Heinäniemi M, Lohi O, Wiita AP, Izraeli S, Geng H, Weinstock DM, Müschen M

CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.

Blood advances

Ramkumar P, Abarientos AB, Tian R, Seyler M, Leong JT, Chen M, Choudhry P, Hechler T, Shah N, Wong SW, Martin TG, Wolf JL, Roybal KT, Pahl A, Taunton J, Wiita AP, Kampmann M